TABLE 2.
Resistance profiles of donor strains and transconjugants
| Group and strain | MIC (μg/ml)
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| CIPa | AMP | CTX | GEN | SXT | SMZ | TMP | CHL | TET | |
| Clinical strains (donors) | |||||||||
| 4 | 64 | ≥512 | ≥512 | ≥512 | ≥512 | ≥512 | ≥128 | ≥512 | ≥512 |
| 7 | 128 | ≥512 | ≥512 | ≥512 | ≥512 | ≥512 | ≥128 | ≥512 | 128 |
| 10 | 128 | ≥512 | ≥512 | ≥512 | ≥512 | ≥512 | ≥128 | 64 | 256 |
| 12 | 128 | ≥512 | ≥512 | ≤1 | ≥512 | ≥512 | ≥128 | 64 | 256 |
| 29 | 64 | ≥512 | 256 | ≤1 | ≥512 | ≥512 | ≥128 | 64 | 256 |
| 76 | ≥256 | ≥512 | 64 | ≥512 | ≥512 | ≥512 | ≥128 | 256 | 256 |
| Recipient, J53Az | 0.008 | 16 | 0.03 | 0.125 | 0.5 | 16 | 0.125 | 4 | 1 |
| Transconjugantsb | |||||||||
| 4-3 | 0.25 | ≥512 | 32 | 8 | ≥512 | ≥512 | ≥128 | 512 | 32 |
| 4-59 | 0.25 | ≥512 | 2 | 0.125 | ≥512 | ≥512 | ≥128 | ≥512 | 64 |
| 7-24.1 | 0.125 | ≥512 | 8 | 2 | ≥512 | ≥512 | ≥128 | 256 | 1 |
| 7-24.2 | 0.125 | 32 | ≤0.03 | 1 | 0.5 | ≥512 | 0.125 | 4 | 1 |
| 10-5 | 0.25 | 32 | ≤0.03 | 0.125 | ≥512 | ≥512 | ≥128 | 4 | 64 |
| 10-2 | 1 | ≥512 | 0.06 | 0.125 | 1 | ≥512 | 0.125 | 4 | 64 |
| 12-4 | 1 | ≥512 | 0.06 | 0.125 | 1 | ≥512 | 0.125 | 4 | 64 |
| 29-11 | 1 | ≥512 | 0.06 | 0.125 | 0.5 | ≥512 | 0.125 | 4 | 64 |
| 76-65 | 2 | ≥512 | 8 | 128 | ≥512 | ≥512 | ≥128 | 256 | 128 |
CIP, ciprofloxacin; AMP, ampicillin; CHL, chloramphenicol; CTX, cefotaxime; GEN, gentamicin; SMZ, sulfamethoxazole; TET, tetracycline; TMP, trimethoprim.
qnr is located on different-size plasmids for transconjugants 4-3 and 4-59, as well as 7-24.1 and 7-24.2, whereas qnr is located on the same-size plasmids for 10-5 and 10-2. For another transconjugant, 12-5, the MICs were the same as those for 12-4.